Search Results - "Ligozio, Shelia"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

    Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials by Ren, Jimin, Rynders, Austin, Evan, Jacob, Evan, Jeremy, Ligozio, Shelia, Ho, Karen S, Sguigna, Peter V, Glanzman, Robert, Hotchkin, Michael T, Dewey, Jr, Richard B, Greenberg, Benjamin M

    Published in Journal of nanobiotechnology (13-12-2023)
    “…Impaired brain energy metabolism has been observed in many neurodegenerative diseases, including Parkinson's disease (PD) and multiple sclerosis (MS). In both…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials

    Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials by Ren, Jimin, Dewey, 3rd, Richard B, Rynders, Austin, Evan, Jacob, Evan, Jeremy, Ligozio, Shelia, Ho, Karen S, Sguigna, Peter V, Glanzman, Robert, Hotchkin, Michael T, Dewey, Jr, Richard B, Greenberg, Benjamin M

    Published in Journal of nanobiotechnology (03-01-2024)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension

    Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension by Vucic, Steve, Menon, Parvathi, Huynh, William, Mahoney, Colin, Ho, Karen S., Hartford, Alan, Rynders, Austin, Evan, Jacob, Evan, Jeremy, Ligozio, Shelia, Glanzman, Robert, Hotchkin, Michael T., Kiernan, Matthew C.

    Published in EClinicalMedicine (01-06-2023)
    “…CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism and reduces oxidative stress. The phase…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionResearch in context

    Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionResearch in context by Steve Vucic, Parvathi Menon, William Huynh, Colin Mahoney, Karen S. Ho, Alan Hartford, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Robert Glanzman, Michael T. Hotchkin, Matthew C. Kiernan

    Published in EClinicalMedicine (01-06-2023)
    “…Background: CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism and reduces oxidative…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: